The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study.

ABSTRACT:

Aim

This study examined the real-world effectiveness and safety outcomes of vedolizumab in ulcerative colitis (UC) patients who had failed anti-tumor necrosis factor (anti-TNF) therapy in Korea.

Methods

A retrospective chart review study was conducted in adults with moderate to severely active UC who had failed anti-TNF agents and subsequently received vedolizumab. Clinical response and clinical remission at week 6 and 14 after vedolizumab initiation was evaluated. Safety outcomes were also reported. Outcome rates were compared with a matched sub-cohort derived from the open-label sub-cohort of the GEMINI 1 trial using the optimal matching method.

Results

A total of 105 patients (mean age, 45.3 years; 63.8% male) were included. At week 6, 55.8% (n = 43/77) achi

SUBMITTER: Ye BD 

PROVIDER: S-EPMC8261845 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature